MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
CBIO - Catalyst Biosciences Inc
$6.03
-0.09(-1.47%)9:00:01 PM 2/26/2021
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase II development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation engineered coagulation Factor IX therapy that has completed Phase IIb clinical trials for the treatment of hemophilia B. The company also develops CB 2679d-GT, an early stage Factor IX gene therapy construct for Hemophilia B; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (AMD); and SQ systemic complement inhibitors pipeline. The company has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/18/2021CBIO
    Catalyst Biosciences to Present at the 42nd Annual Raymond James Institutional Investors Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its executive management team will participate in a fireside chat at the Raymond James 42nd Annual Institutional Investors Conference at 2:10 pm ET on Wednesday, March 3, 2021. To access a live webcast of the presentation, please click here. An archived webcast of the presentation will be available for 90 days on the Events and Presentations section of the ...

    02/11/2021CBIO
    Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced that in connection with its previously announced public offering of its common stock, the underwriters partially exercised and closed their over-allotment option to purchase an additional 485,000 shares of the Company’s common stock, offered at a price of $5.75 per share to the public. The Company received approximately $2.8 million in additional gross proceeds ...

    02/10/2021CBIO
    Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021

    Upgrades For Sealed Air Corp (NYSE:SEE), Seaport Global upgraded the previous rating of Neutral to Buy. Sealed Air earned $0.89 in the fourth quarter, compared to $0.78 in the year-ago quarter. At the moment, the stock has a 52-week-high of $47.90 and a 52-week-low of $17.06. Sealed Air closed at $45.42 at the end of the last trading period. For Blackbaud Inc (NASDAQ:BLKB), Benchmark upgraded the previous rating of Hold to Buy. For the fourth quarter, Blackbaud had an EPS of $0.85, compared to y...

    02/3/2021CBIO
    Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress

    SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented positive pre-clinical data from its Marzeptacog alfa (activated) – MarzAA, program, the Company’s subcutaneously (SQ) administered next-generation engineered activated coagulation Factor VII (FVIIa) for the treatment of episodic bleeding that is entering a Phase 3 registration trial. The data were presented by Tom Knudsen, D.V.M., Ph.D., vice president of translational researc...

    01/29/2021CBIO
    Catalyst Biosciences Announces Closing of Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced the closing of an underwritten public offering of 8,700,000 shares of its common stock, offered at a price of $5.75 per share to the public. The gross proceeds to the Company from this offering were approximately $50 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the shares in...

    01/27/2021CBIO
    Catalyst Biosciences Announces Pricing of Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO (the “Company”) today announced the pricing of an underwritten public offering of 8,700,000 shares of its common stock, offered at a price of $5.75 per share to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,305,000 shares of its common stock. All of the shares in the offering are being offered by the Company. The offering is...

    01/26/2021CBIO
    Catalyst Biosciences Announces Proposed Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it is offering shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Catalyst expects to grant the underwriters of the offering a 30-day option to purchase up to ...